KRAS and non-small cell lung carcinoma: Therefore, here we identified a novel subpopulation of NSCLC patients as caspase-4 positive among which we identified patients as double positive for caspase-4 and K-Ras or c-MyC, and triple positive, identified as caspase-4, K-Ras and c-MyC positive.